The news of Piper Sandler maintaining an Underweight rating on Aemetis and raising the price target from $2 to $3 may not have a significant short-term impact on the stock price. While the increased price target may be seen as a positive signal, the Underweight rating suggests that the analyst still has concerns about the company's performance. Therefore, the overall impact on the stock price is expected to be neutral in the short term.